IP Library › Granted Patent US 8,124,092
Granted Patent B2
US 8,124,092 · App. 12/048,040 · Granted Feb 28, 2012

Antibodies against H5N1 strains of influenza A virus

Assignee: Institute for Research in Biomedicine
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,124,092
App. No.
12/048,040
Granted
Feb 28, 2012
Kind
B2
Abstract

Provided are human antibodies that can neutralize a H5N1 strain of influenza A virus. Also provided are antibodies that can neutralize a strain of influenza A virus in clade 2 of the H5 subtype, that can neutralize a H5N1 strain of influenza A virus and have a lambda light chain, and that are IgG antibodies (but not with a IgG1 heavy chain) that can neutralize a H5N1 strain of influenza A virus.

Claims (20)

1. An isolated antibody, or an antigen binding fragment thereof, that neutralizes a H5N1 strain of influenza A virus comprising the heavy chain CDR1, CDR2 and CDR3 and the light chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 17-22, 23-28, 29-34, 35-40, 45-50, 55-60, 65-70, 75-80, 85-90, 95-100, or 105-110, respectively.

2. The antibody of claim 1 , or an antigen binding fragment thereof, which binds to hemagglutinin present in the virion of a H5N1 strain of influenza A virus.

3. The antibody of claim 1 , or an antigen binding fragment thereof, wherein said antibody comprises a heavy chain variable region comprising SEQ ID NO: 13 and a light chain variable region comprising SEQ ID NO: 15.

4. The antibody of claim 1 , or an antigen binding fragment thereof, wherein said antibody comprises a heavy chain variable region comprising SEQ ID NO: 5 and a light chain variable region comprising SEQ ID NO: 7.

5. The antibody of claim 1 , or an antigen binding fragment thereof, wherein said antibody comprises a heavy chain variable region comprising SEQ ID NO: 9 and a light chain variable region comprising SEQ ID NO: 11.

6. The antibody of claim 1 , or an antigen binding fragment thereof, wherein said antibody comprises a heavy chain variable region comprising SEQ ID NO: 1 and a light chain variable region comprising SEQ ID NO: 3.

7. The antibody of claim 1 , or an antigen binding fragment thereof, wherein said antibody comprises a heavy chain variable region comprising SEQ ID NO: 42 and a light chain variable region comprising SEQ ID NO: 44.

8. The antibody of claim 1 , or an antigen binding fragment thereof, wherein said antibody comprises a heavy chain variable region comprising SEQ ID NO: 52 and a light chain variable region comprising SEQ ID NO: 54.

9. The antibody of claim 1 , or an antigen binding fragment thereof, wherein said antibody comprises a heavy chain variable region comprising SEQ ID NO: 62 and a light chain variable region comprising SEQ ID NO: 64.

10. The antibody of claim 1 , or an antigen binding fragment thereof, wherein said antibody comprises a heavy chain variable region comprising SEQ ID NO: 72 and a light chain variable region comprising SEQ ID NO: 74.

11. The antibody of claim 1 , or an antigen binding fragment thereof, wherein said antibody comprises a heavy chain variable region comprising SEQ ID NO: 82 and a light chain variable region comprising SEQ ID NO: 84.

12. The antibody of claim 1 , or an antigen binding fragment thereof, wherein said antibody comprises a heavy chain variable region comprising SEQ ID NO: 92 and a light chain variable region comprising SEQ ID NO: 94.

13. The antibody of claim 1 , or an antigen binding fragment thereof, wherein said antibody comprises a heavy chain variable region comprising SEQ ID NO: 102 and a light chain variable region comprising SEQ ID NO: 104.

14. The antibody of claim 1 , or an antigen binding fragment thereof, wherein the antibody is selected from the group consisting of FLA5.10, FLD21.140, FLA3.14, FLD20.19, FLD84, FLD93, FLD122, FLD127, FLD129, FLD132 and FLD194.

15. The antibody of claim 1 , wherein the antibody has a λ light chain.

16. The antibody of claim 1 , wherein the antibody does not have a IgG1 heavy chain.

17. A pharmaceutical composition comprising a first antibody, or an antigen binding fragment thereof, of claim 1 , and a second, different antibody, or an antigen binding fragment thereof, wherein the first and second antibodies do not cross-compete with each other.

18. The antibody of claim 1 , or a fragment thereof, wherein said antibody is a monoclonal antibody or a human antibody.

19. An antibody, or an antigen binding fragment thereof, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 13 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 15; or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 5 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 7; or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 9 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 11; or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 3; or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 42 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 44; or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 52 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 54; or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 62 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 64; or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 72 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 74; or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 82 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 84; or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 92 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 94; or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 102 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 104, wherein the antibody or antigen binding fragment neutralizes a H5N1 strain of influenza A virus.

20. A pharmaceutical composition comprising two monoclonal antibodies of claim 1 , or antigen binding fragments thereof, wherein the antibodies do not cross-compete with each other.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2008
From: LANZAVECCHIA, ANTONIO
To: HUMAB, LLC
Reel/Frame 021384/0133 →
Continuity (2)
Provisional Application 60894612 · Mar 13, 2007
Related Publication 20100278834A1 · Nov 4, 2010